Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents

• DOI: 10.1001/jamanetworkopen.2022.0935
• Publication Date: 2022-03-03T11:33:34Z
• Authors: Carlos R. Oliveira; Linda M. Niccolai; Hassan Sheikha; Lina Elmansy; Chaney C. Kalinich; Nathan D. Grubaugh; Eugene D. Shapiro; ; Kendall Billig; Mallery I. Breban; Anderson Brito; Rebecca Earnest; Joseph R. Fauver; Tobias Koch; Isabel Ott; Mary Petrone; Chantal B.F. Vogels; Kien Pham; Irina Tikhonova; Christopher Castaldi; Shrikant Mane; Kaya Bilguvar; Bony De Kumar; David Ferguson; Nicholas Kerantzas; Marie Landry; David Peaper; Wade Schulz
• Keywords: Odds; Medical record

The emergence of the B.1.617.2 (Delta) variant SARS-CoV-2 has led to increases in both infections and hospitalizations among adolescents. Little is known about effectiveness BNT162b2 vaccine adolescents general population, as opposed a clinical trial population.To estimate aged 12 18 years.This was matched case-control study (aged 12-18 years) who had results from reverse transcription-polymerase chain reaction (RT-PCR) test. Immunization histories, relevant data, RT-PCR test were obtained Yale New Haven Health System's medical records between June 1, 2021, August 15, when Delta caused 92% Connecticut. Case participants defined positive result an associated encounter. Control those negative case participant by age, county residence, date testing.Adolescents fully immunized if they received 2 doses at least 14 days before focal time.The primary outcome measured infection confirmed RT-PCR. vaccine's (VE) estimated using odds ratios conditional logistic regression models. Secondary measures included VE symptoms, number received, elapsed time immunization.A total 6901 tested for SARS-CoV-2. final sample comprised 186 356 control participants. median age (IQR, 13-16) years, 262 (48%) identified female, 81 (15%) Black, 82 Hispanic, 297 (55%) White. Overall, 134 (25%) (case participants, 10 [5%]; 124 [35%]). immunization 62 (range, 17-129 days). Within 4 months receiving doses, against any be 91% (95% CI, 80%-96%); asymptomatic infection, 85% 57%-95%). Effectiveness after single dose 74% 18%-92%).In this retrospective US adolescents, appeared provide excellent protection symptomatic infections.